A Study of Subcutaneous Gefurulimab Using Prefilled Syringe Versus Autoinjector in Healthy Adult Participants

Exclusion Criteria

• •1. History of any Neisseria meningitidis infection.
• •2. History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological disorders.
• •3. Abnormal blood pressure as determined by the Investigator.
• •4. History of latent or active TB (Tuberculosis) or exposure to endemic areas.
• •5. Allergy to monoclonal antibodies.
• •6. Clinically significant multiple or severe drug allergies, intolerance to topical corticosteroids, or severe posttreatment hypersensitivity reactions.
• •7. Lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years.
• •8. Current or chronic history of liver disease.
• •9. Known hepatic or biliary abnormalities.
• •10. Active systemic bacterial, viral, or fungal infection within 14 days prior to dosing.
• •11. History of allergy or intolerance to penicillin or cephalosporin.
• •12. History of clinically significant allergic reaction (eg, anaphylaxis or angioedema) to any product.
• •13. Live vaccine(s) within 1 month prior to Screening or plans to receive such vaccines during the study.
• •14. Evidence of human immunodeficiency virus (HIV) infection (positive HIV type 1 or type 2 antibody).
• •15. Evidence of hepatitis B infection (positive hepatitis B surface antigen \[HBsAg\] or positive total hepatitis B core antibody \[HBcAb\] with negative surface antibody \[anti-HBs\]), or hepatitis C viral infection (positive HCV RNA).
• •16. Female participants who have a positive pregnancy test at Screening or Admission.
• •17. Positive prestudy drug/alcohol screen; positive result may be repeated once.